Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy

Evaxion Biotech A/S EVAX has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.
In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma.
"We are thrilled to announce promising interim data from the first eight patients...All patients demonstrated a specific T-cell immune response induced by the treatment, confirming the potential capabilities of our AI platform technology," said CEO Per Norlén.
Personalized cancer immunotherapy, like EVX-02, is particularly challenging to produce because a new and unique drug is manufactured for each patient.
The treatment appeared to be well tolerated in all patients, with only very mild adverse events (AEs) observed in relation to EVX-02 treatment.
EVX-02 induced CD4+ and CD8+ specific T-cell responses in all patients, providing proof of mechanism for DNA-delivery technology, in that the delivered EVX-02-DNA gave rise to immune reactions to its encoded neoantigen peptides. The T-cell responses were robust and long-lasting.
A full clinical trial report for the EVX-02 Phase 1 study is expected in the second quarter of 2023.
Price Action: EVAX shares traded higher by 0.92% at $2.24 on the last check Thursday.